Cagrilintide vs NAD+
Cagrilintide and NAD+ are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: Cagrilintide is lipidated 37-residue amylin analogue, cys2–cys7 disulfide, c-terminal prolinamide, while NAD+ is dinucleotide coenzyme — not a peptide — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus sterile or bacteriostatic water); their leading degradation routes differ (fibrillation for Cagrilintide, alkaline hydrolysis for NAD+), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
Cagrilintide — origin
Cagrilintide is an engineered analogue of human amylin (IAPP), the 37-residue hormone co-secreted with insulin from pancreatic beta cells. Its design problem was unusually specific: native amylin is strongly amyloidogenic, readily collapsing from helix into the beta-sheet conformation that seeds fibrils, which is what made a long-acting amylin drug difficult for decades. Cagrilintide carries six substitutions relative to human amylin (14E, 17R, 25P, 28P, 29P, 37P) — roughly 84% sequence homology — plus N-terminal acylation with a C20 fatty diacid through a gamma-glutamate linker.
NAD+ — origin
NAD+ is not a peptide at all, and that single fact governs everything about how it is handled. It is a dinucleotide coenzyme — nicotinamide and adenine linked through a pyrophosphate bridge — present in every living cell and central to redox metabolism. It was first identified in 1906 by Arthur Harden as a small heat-stable factor required for yeast fermentation.
Cagrilintide research themes
Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.
A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.
The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.
The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.
NAD+ research themes
Sirtuins consume NAD+ as a co-substrate, which links cellular NAD+ availability directly to their activity.
Its canonical role as the central redox carrier of cellular respiration.
PARP enzymes consume NAD+ during DNA damage response, a heavily studied competing demand.
A major driver of current research interest: measured NAD+ levels fall with age across tissues in animal models.
Cagrilintide handling
- Never shake. Swirl gently and allow the cake to dissolve in its own time.
- Do not freeze reconstituted solution.
- Add diluent down the vial wall rather than directly onto the cake.
- Treat visible particulate or a settling precipitate as a rejected vial — for an amylin analogue this is the observable end of the fibrillation pathway, not a cosmetic issue.
NAD+ handling
- Allow the sealed vial to reach room temperature before opening — opening a cold vial of hygroscopic material condenses water directly onto it.
- Keep solutions at or below neutral pH; alkaline conditions destroy NAD+ quickly.
- Prepare fresh solutions where concentration accuracy is important rather than relying on stored stock.
- Protect from light at all stages.
Both third-party tested
Every Popular Peptides batch of Cagrilintide and NAD+ is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
Cagrilintide reference
Related comparisons
Cagrilintide and NAD+ are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.